NCT03475719Unknown1 期
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristic After Administration of Fixed-dose Combination or Loose Combination of HUG186 in Healthy Adult Male or Menopausal Female Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- AUC0-t of Bazedoxifene
研究概览
简要总结
A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men, age≥19 years of age, Postmenopausal women are eligible. Postmenopausal is defined as any of the following:
- •Amenorrhea for 12 or more months
- •FSH and estradiol in the postmenopausal range per local normal range.
- •Body weight of ≥ 55 kg, BMI 18.5 to 30.0
- •No morbid symptom or sign, based on physical examination, with no innate or chronic disease.
- •Subject that is considered appropriate for participating in the study by an investigator, based on clinical laboratory test (hematology, clinical chemistry, urinalysis) that is performed according to the characteristics of investigational drugs.
- •Subject that agree to apply sun cream in case of daylight exposure for more than 1hours
- •Subjects must be able to listen to and understand the detailed statement of informed consent, and willing to decide to participate in the study, follow the study directions and provide written informed consent.
排除标准
- •A clinically significant disease or history in hepatobiliary system, kidney, digestive system, respiratory system, hemato-oncological system, endocrine system, neuro-psychiatric system, musculo-skeletal system, immune system, otorhinolaryngological system or cardiovascular system.
- •A history of hypersensitivity to investigational drugs and its additives or clinically significant hypersensitivity to any other drug.
- •History of drug abuse, or positive in drug screening test.
- •Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.
- •Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of investigational drug, and this will affect this study or the safety of the subjects at discretion of study investigator.
- •Participation in another clinical trial or a bioequivalent study within 3 months prior to the first administration of investigational drug (The finish time of previous study is the day of the last administration of study drug)
- •Whole blood donation within 2 months or component donation within 1 month, prior to the first administration of investigational drug, or transfusion within 1 month prior to the first administration of investigational drug.
- •Prolonged excessive alcohol consumption (>21 units/week, 1 unit=10g of pure alcohol), or subjects who can not abstain from drinking from 24 hours prior to hospitalization until the discharge.
- •Smoking more than 10 cigarettes per day, excessive caffeine consumption (example: instant coffee > 5 cups/day)
- •Subjects who are judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result
研究组 & 干预措施
HUG186-B and HUG186-D
Active Comparator
Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
干预措施: HUG186-B and HUG186-D (Drug)
HUG186
Experimental
Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
干预措施: HUG186 (Drug)
结局指标
主要结局
AUC0-t of Bazedoxifene
时间窗: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)
Area under the curve(AUCt) of Bazedoxifene
Cmax of Bazedoxifene
时间窗: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)
Maximum observed concentration(Cmax) of Bazedoxifene
AUC0-t of Cholecalciferol
时间窗: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)
Area under the curve(AUCt) of Cholecalciferol
Cmax of Cholecalciferol
时间窗: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)
Maximum observed concentration(Cmax) of Cholecalciferol
次要结局
- AUCinf of Cholecalciferol(-24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points))
- Tmax of Bazedoxifene(0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points))
- AUCinf of Bazedoxifene(0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points))
- Tmax of Cholecalciferol(-24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points))
- t1/2 of Bazedoxifene(0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points))
- t1/2 of Cholecalciferol(-24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus ErythematosusLupus ErythematosisNCT06468683Shanghai Simnova Biotechnology Co.,Ltd.50
招募中
1 期
A Phase 1 Study of BB102 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06258408Broadenbio Ltd., Co.78
招募中
1 期
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous NephropathyPrimary Membranous NephropathyNCT05668403Shanghai Jiaolian Drug Research and Development Co., Ltd52
Unknown
1 期
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or LymphomasAdvanced Solid Tumors or LymphomasNCT05374226Suzhou Kebo Ruijun Biotechnology Co., Ltd172
Unknown
1 期
A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05508373Suzhou Kebo Ruijun Biotechnology Co., Ltd72